CORALVILLE, Iowa--(BUSINESS WIRE)--Voxello, developer of communication solutions for impaired hospitalized patients, today announced that Richard Wieland was appointed as a new member of the Company's Board of Directors. Mr. Wieland will also serve as the interim Chief Financial Officer.
Mr. Wieland is a senior financial executive with a diversified Life Science business background with more than thirty-five years of business experience in both public and private companies. He completed over twenty capital transactions including two successful IPOs and eleven M&A transactions. Subsequent to the M&A transactions, he successfully managed the post-acquisition integration programs.
Most recently, Rich was Executive Vice President and Chief Financial officer of Unilife Corporation, a NASDAQ-traded medical device company. Prior to Unilife he spent six years at two biotech companies in the drug discovery and development field both of whom had products in clinical development. Previous to that Rich had P&L responsibility for two healthcare companies and was a member of the Board of Directors at Option Care Inc., a NASDAQ-traded home healthcare company that was subsequently acquired by Walgreen’s. His first CFO position was with LyphoMed Inc., a generic pharmaceutical company with revenues of ~ $225 million that was eventually acquired by Fujisawa Pharmaceutical Co. Ltd. Rich began his career at Procter & Gamble Company in Cincinnati, OH.
Rich earned an MBA degree in finance from the Olin School of Business at Washington University in St. Louis, MO and an undergraduate degree in accounting and economics from Monmouth College in Monmouth, IL. Rich was a member of the Signal Corps in the Army and served on the Alumni Board of Monmouth College. After Fujisawa acquired LyphoMed, he established the Wieland Family Foundation that supports charities for disadvantaged children.
“We are very pleased to have Mr. Wieland join our Board of Directors. His life sciences background coupled with his financial and management experience will add significantly to the depth of our already outstanding board, as well as position us for the successful execution of our strategic plan for the Company,” said Rives Bird, CEO of Voxello.
Richard Wieland added, “I am pleased to have the opportunity to join the Board of Directors at Voxello. Voxello has a unique opportunity within the hospital market with the noddle™, the Company’s first offering, which allows impaired hospitalized patients who cannot communicate by traditional means to communicate. It’s quite uncommon to find a solution that can provide a tremendous ROI to the hospital, improve patient satisfaction, and comply with new regulations from the Joint Commission for accreditation. Pending FDA clearance the Company plans to launch in key markets. I am looking forward to working with Rives Bird, to help build value for the shareholders.”
About Voxello
Voxello provides solutions for impaired hospitalized patients who cannot communicate by traditional means. The company’s first product, the noddle™, detects voluntary gestures such as clicking sounds made with the tongue or an eye blink to control nurse call and speech generation devices. For more information about Voxello, please visit www.voxello.com.
